Disparate results in studies of methotrexate plus corticosteroids in the treatment of giant cell arteritis: Comment on the article by Hoffman et al
Juan Angel Jover MD, PhD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorCesar Hernández-Garcia MD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorInmaculada C. Morado MD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorEmilio Vargas MD, PhD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorAntonio Bañares MD, PhD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorBenjamin Fernandez-Gutierrez MD, PhD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorJuan Angel Jover MD, PhD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorCesar Hernández-Garcia MD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorInmaculada C. Morado MD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorEmilio Vargas MD, PhD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorAntonio Bañares MD, PhD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this authorBenjamin Fernandez-Gutierrez MD, PhD
Hospital Clínico San Carlos, Madrid, Spain
Search for more papers by this author
References
- 1 Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al, for the International Network for the Study of Systemic Vasculitides (INSSYS). A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309–18.
- 2 Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Guitiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106–14.
- 3 Fernando del Rosario J, Orenstein SR, Neigut DA, Giarusso V, Wolfson N, Kocoshis SA. Retrospective analysis of alternate-day prednisone maintenance therapy for Crohn's disease. Clin Pediatr 1998; 37: 413–9.
- 4 Sommer N, Sigg B, Melms A, Weller M, Schelpelmann K, Herzau V, et al. Myasthenia gravis: response to long-term immunosuppressive treatment. Neurol Neurosurg Psych 1997; 62: 156–62.
- 5
Potter MB,
Fincher RK,
Finger DR.
Eosinophilia in Wegener's granulomatosis.
Chest
1999;
116:
1480–3.
10.1378/chest.116.5.1480 Google Scholar
- 6 Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int 1999; 55 Suppl 70: S56–62.
- 7 Barnard J, Newman LS. Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 2001; 13: 84–91.
- 8 Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975; 82: 613–8.
- 9 Spiera RF, Mitnick HJ, Kupersmith M, Richnomd M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19: 495–501.
